FDA
-
-
-
-
-
-
-
TD Cowen Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)
-
-
-
-
-
-
-
Piper Sandler Highlights Top Picks in the Biopharma 2026 Preview Note
-
-
-
-
-
-
-
Praxis Precision Medicines Inc. (PRAX) PT Raised to $315 at Needham
-
-
-
-
-
-
-
Praxis receives FDA alignment on ulixacaltamide NDA submission plans
-
-
-
-
-
-
-
Praxis announces accelerated development path for relutrigine in SCN2A and SCN8A DEE patients following positive FDA feedback
-
-
-
-
-
-
-
Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline
-
-
-
-
-
-
-
Guggenheim on Praxis Precision Medicines Inc. (PRAX): 'remains one of our Top Picks for 2025'
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

